145 related articles for article (PubMed ID: 14607312)
1. A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a.
Zivadinov R; Zorzon M; Tommasi MA; Nasuelli D; Bernardi M; Monti-Bragadin L; Cazzato G
J Neurol Sci; 2003 Dec; 216(1):113-8. PubMed ID: 14607312
[TBL] [Abstract][Full Text] [Related]
2. Interferon-beta-1a treatment has a positive effect on quality of life of relapsing-remitting multiple sclerosis: results from a longitudinal study.
Patti F; Pappalardo A; Montanari E; Pesci I; Barletta V; Pozzilli C
J Neurol Sci; 2014 Feb; 337(1-2):180-5. PubMed ID: 24433926
[TBL] [Abstract][Full Text] [Related]
3. An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects.
Phillips JT; Fox E; Grainger W; Tuccillo D; Liu S; Deykin A
BMC Neurol; 2011 Oct; 11():126. PubMed ID: 21999176
[TBL] [Abstract][Full Text] [Related]
4. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
Herndon RM; Rudick RA; Munschauer FE; Mass MK; Salazar AM; Coats ME; Labutta R; Richert JR; Cohan SL; Genain C; Goodkin D; Toal M; Riester K
Mult Scler; 2005 Aug; 11(4):409-19. PubMed ID: 16042223
[TBL] [Abstract][Full Text] [Related]
5. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
Durelli L; Verdun E; Barbero P; Bergui M; Versino E; Ghezzi A; Montanari E; Zaffaroni M;
Lancet; 2002 Apr; 359(9316):1453-60. PubMed ID: 11988242
[TBL] [Abstract][Full Text] [Related]
6. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.
Cohen JA; Cutter GR; Fischer JS; Goodman AD; Heidenreich FR; Kooijmans MF; Sandrock AW; Rudick RA; Simon JH; Simonian NA; Tsao EC; Whitaker JN;
Neurology; 2002 Sep; 59(5):679-87. PubMed ID: 12221157
[TBL] [Abstract][Full Text] [Related]
7. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study.
Clanet M; Kappos L; Hartung HP; Hohlfeld R;
Mult Scler; 2004 Apr; 10(2):139-44. PubMed ID: 15124757
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS.
Clanet M; Radue EW; Kappos L; Hartung HP; Hohlfeld R; Sandberg-Wollheim M; Kooijmans-Coutinho MF; Tsao EC; Sandrock AW;
Neurology; 2002 Nov; 59(10):1507-17. PubMed ID: 12451189
[TBL] [Abstract][Full Text] [Related]
9. Quality of life in multiple sclerosis: influence of interferon-beta1 a (Avonex) treatment.
Vermersch P; de Seze J; Delisse B; Lemaire S; Stojkovic T
Mult Scler; 2002 Oct; 8(5):377-81. PubMed ID: 12356203
[TBL] [Abstract][Full Text] [Related]
10. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
[TBL] [Abstract][Full Text] [Related]
11. Influence of Interferon beta treatment on quality of life in multiple sclerosis patients.
Simone IL; Ceccarelli A; Tortorella C; Bellacosa A; Pellegrini F; Plasmati I; De Caro MF; Lopez M; Girolamo F; Livrea P
Health Qual Life Outcomes; 2006 Dec; 4():96. PubMed ID: 17163989
[TBL] [Abstract][Full Text] [Related]
12. Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis.
Mohr DC; Likosky W; Dwyer P; Van Der Wende J; Boudewyn AC; Goodkin DE
Arch Neurol; 1999 Oct; 56(10):1263-5. PubMed ID: 10520943
[TBL] [Abstract][Full Text] [Related]
13. Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a.
Miller DM; Weinstock-Guttman B; Bourdette D; You X; Foulds P; Rudick RA
Mult Scler; 2011 Jun; 17(6):734-42. PubMed ID: 21300736
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life in patients with relapsing-remitting multiple sclerosis treated with subcutaneous interferon β-1a in Iran.
Pakdaman H; Amini Harandi A; Gharagozli K; Abbasi M; Tabassi A; Ashrafi F; Ghaffarpor M; Sharifi S; Delavar Kasmae H; Assarzadegan F; Arabahmadi M; Behnam B
Int J Neurosci; 2017 Jun; 127(6):501-507. PubMed ID: 27279451
[TBL] [Abstract][Full Text] [Related]
15. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study.
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Picconi O; Cilia S; Cottone S; Centonze D; Gasperini C;
Mult Scler; 2011 Aug; 17(8):991-1001. PubMed ID: 21502310
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.
Bertolotto A; Malucchi S; Sala A; Orefice G; Carrieri PB; Capobianco M; Milano E; Melis F; Giordana MT
J Neurol Neurosurg Psychiatry; 2002 Aug; 73(2):148-53. PubMed ID: 12122172
[TBL] [Abstract][Full Text] [Related]
17. fMRI changes in relapsing-remitting multiple sclerosis patients complaining of fatigue after IFNbeta-1a injection.
Rocca MA; Agosta F; Colombo B; Mezzapesa DM; Falini A; Comi G; Filippi M
Hum Brain Mapp; 2007 May; 28(5):373-82. PubMed ID: 16933299
[TBL] [Abstract][Full Text] [Related]
18. Quality of life during the first 6 months of interferon-beta treatment in patients with MS.
Arnoldus JH; Killestein J; Pfennings LE; Jelles B; Uitdehaag BM; Polman CH
Mult Scler; 2000 Oct; 6(5):338-42. PubMed ID: 11064444
[TBL] [Abstract][Full Text] [Related]
19. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group.
Simon JH; Lull J; Jacobs LD; Rudick RA; Cookfair DL; Herndon RM; Richert JR; Salazar AM; Sheeder J; Miller D; McCabe K; Serra A; Campion MK; Fischer JS; Goodkin DE; Simonian N; Lajaunie M; Wende K; Martens-Davidson A; Kinkel RP; Munschauer FE
Neurology; 2000 Jul; 55(2):185-92. PubMed ID: 10908888
[TBL] [Abstract][Full Text] [Related]
20. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
